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ABSTRACT
Background. In the peripheral blood, the neutrophil–
lymphocyte ratio (NLR) and platelet–lymphocyte ratio
(PLR) change in response to malignancy. These biomark-
ers are associated with adverse outcomes in numerous
cancers, but the evidence is limited in relation to mela-
noma. This study sought to investigate the association
between these biomarkers and survival in Stages I–III
cutaneous melanoma.
Methods. This multicenter cohort study investigated a
consecutive series of patients who underwent wide excision
of biopsy-proven cutaneous melanoma and sentinel lymph
node biopsy during a 10-year period. The baseline NLR
and PLR were calculated immediately before sentinel
lymph node biopsy. Adjusted hazard ratios (HRs) for
overall and melanoma-specific survival were generated.
Results. Overall, 1351 patients were included in the study.
During surveillance, 184 of these patients died (14%), with
141 of the deaths (77%) attributable to melanoma. Worse
overall survival was associated with a baseline NLR lower
than 2.5 [HR 2.2; 95% confidence interval (CI) 2.0 to 2.3;
p\ 0.001] and a baseline PLR lower than 100 (HR 1.8;
95% CI 1.7 to 1.8; p\ 0.001). Melanoma-specific survival
also was worse, with a baseline NLR lower than 2.5 (HR
1.9; 95% CI 1.6 to 2.2; p\ 0.001) and a baseline PLR
lower than 100 (HR 1.9; 95% CI 1.7 to 2.2; p\ 0.001).
The 5-year survival for patients with sentinel lymph node
metastases and a low NLR and PLR was approximately
50%.
Conclusion. This study provides important new data on
biomarkers in early-stage melanoma, which contrast with
biomarker profiles in advanced disease. These biomarkers
may represent the host inflammatory response to melanoma
and therefore could help select patients for adjuvant ther-
apy and enhanced surveillance.
Cutaneous melanoma represents 7% of skin cancers but
is responsible for 78% of skin cancer-related deaths. Its
incidence in the Western world is rising faster than that of
any other major cancer, and the United Kingdom has more
than 15,000 new diagnoses annually.1
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The survival rate is higher than 90% for Stage I and II
disease, but the presence of regional or distant metastases
reduces the 5-year relative survival rate to 50–55% for
Stage I and to 8–25% for Stage II disease.1 Currently, the
most powerful staging investigation for American Joint
Committee on Cancer (AJCC) Stages IB to IIC melanoma
(comprising approximately 55% of patients with invasive
primaries)2 is sentinel lymph node biopsy (SLNB).
Numerous algorithms to predict survival from clinical and
histopathologic features exist, but these have modest
diagnostic accuracy at best. It is well-established that the
addition of host biomarkers to predictive models improves
their accuracy, and an unmet need for these data in cuta-
neous melanoma remains.
The typical host response to malignancy involves neu-
trophilia, monocytosis, thrombophilia, and
lymphocytopenia.3–6 Changes in these peripheral blood
counts are best represented by their ratios, namely, the
neutrophil–lymphocyte ratio (NLR), the platelet–lympho-
cyte ratio (PLR), and the lymphocyte-monocyte ratio
(LMR). An increased NLR and PLR and a decreased LMR
predict poor survival, recurrence, and response to therapy
for many solid organ tumors.7–9 An abnormal baseline
NLR is associated with adverse outcomes in advanced and
high-risk melanoma,10–14 but has not been investigated for
Stages I–III melanoma.
We hypothesized that NLR, PLR, and LMR baselines
are associated with overall and melanoma-specific survival
in Stages I–III cutaneous melanoma.
PATIENTS AND METHODS
Study Design and Patients
This retrospective cohort study investigated consecutive
patients who underwent wider re-excision (wide local
excision [WLE]) of primary cutaneous melanoma and
SLNB between 2006 and 2016 at the host institutions. A
secure electronic database was prospectively completed by
the direct clinical care team during the study period and
retrospectively augmented using electronic hospital sys-
tems. Approval was gained from the research and ethical
committees of Leeds Teaching Hospitals (reference PL15/
368) and the National Health Research Authority for
Norwich (IRAS project ID 234565).
Over 10 years, we included patients with a biopsy-pro-
ven primary cutaneous melanoma confirmed by study
centre pathologists, who underwent WLE and SLNB. The
following exclusion criteria ruled out patients with no full
blood count (FBC) recorded between the time of initial
biopsy and SLNB; the presence of factors that may have
changed peripheral blood counts such as concurrent
malignancy or infection, pregnancy, chronic inflammatory
conditions, immunosuppressive medications, and prolifer-
ative hematopoietic disorders; and patients with multiple or
occult primaries, second recurrences, or unidentifiable or
unclassifiable tumors.
Variables
All histopathologic features of the primary tumor (tumor
diameter [mm], Breslow thickness [mm], mitotic count per
mm2, the presence of ulceration, angiolymphatic and per-
ineural invasion, microsatellites, tumor-infiltrating
lymphocytes [TILs], and tumor regression) were recorded
and changed accordingly where WLE yielded residual
melanoma. Clinical stage was determined according to the
seventh edition of the American Joint Committee on
Cancer.15
We used the results of the baseline FBC (total white cell
count; absolute neutrophil, lymphocyte, monocyte, and
platelet counts) obtained after excision biopsy but before
WLE and SLNB. If multiple blood tests were performed
during this period, we used the result closest SLNB. Sub-
sequently, NLR (absolute neutrophil 7 absolute
lymphocyte count), PLR (absolute platelet 7 absolute
lymphocyte count), and LMR (absolute lymphocyte 7
absolute monocyte count) were computed.
Outcomes
The primary outcome was survival. For overall survival,
patients were censored if they were lost to follow-up or had
died of any cause. For those who had died, melanoma-
specific survival was defined as death directly
attributable to melanoma.
Sample Size
To achieve 90% power at 5% significance with a 4:1
sampling ratio (because 25% of cases have sentinel lymph
node metastases16), we required 318 participants (n1 = 64,
n2 = 254) to detect an overall survival hazard ratio of 1.5
using a two-tailed log-rank test.10,17,18 Because this was
part of a larger study, we recruited more than the desired
sample size to power other outcomes.
Statistical Analysis
Optimal thresholds for NLR (2.5), PLR (100), and LMR
(9) were determined via Cutoff Finder using the Manhattan
distance.19 The risk for outcomes according to baseline
biomarkers were estimated by complete case analyses
using uni- and multivariable Cox regression to generate
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hazard ratios (HRs) and 95% confidence intervals (CIs)
adjusted for clustering. Covariates for the multivariable
models were known confounders and prescribed in our
protocol. Log-rank statistics accompanied Kaplan–Meier
plots. Models were internally validated with lossless non-
parametric bootstrapping by resampling with replacement,
with 1000 iterations, as per TRIPOD.20 All tests were two-
sided, and significance was set at 5%.
RESULTS
For this study, 2300 patients were eligible, 1503 (65%)
of whom had a relevant blood test. The median time from
blood test to SLN biopsy was 4 days (interquartile range
[IQR], 6 to 9 days). After 152 exclusions, 1351 patients
(59%) remained for analysis (Fig. 1). The baseline char-
acteristics are shown in Table 1. The geometric mean
follow-up period was 3.5 years (95% CI 3.3 to 3.6 years;
median, 3.8 years; minimum, 3 months; maximum,
10.7 years). During surveillance, 184 patients (14%) died,
with 141 (77%) of those deaths attributable to melanoma.
The baseline blood counts of the survivors did not differ
significantly from the counts of those who died, and no
significant differences were observed in the absolute counts
of neutrophils (median difference, 0.1; 95% CI - 0.3 to
0.2), lymphocytes (median difference, 0.1; 95% CI - 0.04
to 0.1), platelets (median difference, 6; 95% CI - 4 to 16),
or monocytes (median difference, - 0.02; 95% CI - 0.04
to 0.1). This observation was similar for those who died of
melanoma compared with survivors, as shown in Table 2.
We observed no univariable associations between
biomarkers and survival. After adjustment for confounders,
multivariable analyses showed that a baseline NLR lower
than 2.5 was associated with worse overall survival (ad-
justed HR 2.2; 95% CI 2.0 to 2.3) and worse melanoma-
specific survival (adjusted HR 1.9; 95% CI 1.6 to 2.2;
Table 2), meaning that patients with a low baseline NLR
were at twice the risk of death during a 10-year period. A
similar association remained when the biomarker was
modeled as a continuous predictor, whereby for every unit
increase in NLR, the risk of death decreased by 20%.
Similarly, an adjusted baseline PLR lower than 100 was
significantly associated with worse overall survival (HR
1.8; 95% CI 1.7 to 1.8) and melanoma-specific survival
(HR 1.9; 95% CI 1.7 to 2.2; Table 2), meaning that patients
with a low baseline PLR were at approximately twice the
risk of death from melanoma during a 10-year period. In
addition, PLR was significantly associated with the out-
come when modeled as a continuous predictor, although
the increments were too small to be clinically meaningful.
Potentially eligible 
patients (n=2261)
Excluded:
•  Unidentifiable patients (n=38)
Excluded:
Excluded:
• No preoperative blood count (n=758)
•  Duplicate patient (n=1)
•  Other cutaneous malignancy (n=44)
•  Non-primary melanoma (n=27)
•  Concurrent malignancy (n=20) 
•  Multiple synchronous primaries (n=19) 
•  Inflammatory conditions (n=14) 
•  Immunosuppressant medication (n=12) 
•  Myeloproliferative disordes (n=6) 
•  Pregnancy (n=4) 
•  Concurrent infection (n=4) 
• Unidentifiable neoplasm (n=2) 
WLE and SLN biopsy
 (n=2300)
Eligible patients 
(n=1503)
Analysed (n=1351)
FIG. 1 Participant flow
diagram
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The patients with a low NLR and PLR were at three
times the risk of death during a 10-year period (HR 3.0;
95% CI 2.4 to 3.7; Fig. 2a), overall and from melanoma
specifically (HR 3.0; 95% CI 2.0 to 4.2; Fig. 2b). This
suggests that patients with both a low NLR and a low PLR
are at the greatest risk of death. All associations were
strengthened by bootstrapping (Table 2). The associations
between known clinicopathologic factors and overall sur-
vival are available online in the supplementary material
(Table 3).
Stratification of the cohort by SLNB status showed that
those with nodal disease and a low NLR and PLR have
significantly worse overall survival (Fig. 3a) and mela-
noma-specific survival (Fig. 3b). The presence of sentinel
lymph node metastases alongside a low baseline NLR and
PLR was associated with four times the risk of death (HR
4.4; 95% CI 2.3 to 8.3; p\ 0.001; Fig. 3a, orange line),
and the median overall survival was 8 months less (IQR 2
to 15 months) than for the patients with a high NLR and
PLR (Fig. 3a, green line). Similarly, nodal metastases with
a low NLR and PLR were associated with almost six times
the risk of death from melanoma (HR 5.8; 95% CI 3.0 to
11.5; p\ 0.001; Fig. 3b, orange line), and the median
melanoma-specific survival was 7 months less (IQR 2 to
15 months) than for the patients with a high NLR and PLR
(Fig. 3b, green line).
TABLE 1 Baseline characteristics
NLR\ 2.5
(n = 789)
n (%)
NLR C 2.5
(n = 562)
n (%)
p Value
Mean age (95% CI)a 59 (58 to 60) 63 (61 to 64) \0.001
Sex (%)
Male 368 (47) 310 (55) 0.002
Female 421 (53) 252 (45)
Median Breslow thickness: mm (IQR) 1.9 (1.2 to 3.1; 0.3 to 24) 1.9 (1.2 to 3; 0.5 to 15) 0.9
Median mitoses: mm-2 (IQR) 3 (1 to 7) 3 (2 to 8) 0.6
Median maximum diameter: mm (IQR) 10 (7 to 14) 11 (7 to 15) 0.2
Ulceration 196 (27) 127 (24) 0.3
Angiolymphatic invasion 21 (6) 12 (5) 0.4
Perineural invasion 14 (4) 10 (4) 0.9
Regression 40 (12) 53 (21) 0.003
Microsatellites 15 (4) 14 (6) 0.6
Tumor-infiltrating lymphocytes
Absent 53 (16) 39 (16) 0.2
Non-brisk 222 (69) 152 (63)
Brisk 48 (15) 50 (21)
Vertical growth phase 297 (97) 232 (99) 0.2
Pathologic subtype
Nodular 87 (11) 57 (10) N/A
Superficial spreading 230 (29) 179 (32)
Acral 12 (2) 10 (2)
Other 460 (58) 316 (56)
Sentinel lymph node(s) containing metastatic melanoma 148 (19) 126 (22) 0.1
Extracapsular spread 12 (16) 4 (7) 0.08
AJCC Stage after sentinel lymph node biopsy
I 518 (66) 372 (66) 0.04
II 121 (15) 63 (11)
III 148 (18) 126 (22)
NLR neutrophil–lymphocyte ratio; CI confidence interval; IQR interquartile ratio; N/A not applicable
aGeometric mean
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The patients with regression of their primary tumor had a
significantly higher median NLR (median difference, 0.3;
IQR 0.1 to 0.5; p = 0.02) and a lower median LMR (median
difference, 0.4; IQR 0.1 to 0.8; p = 0.02). However, no
significant associations were observed between the NLR,
PLR or LMR and the TILs status of the primary tumor.
DISCUSSION
This retrospective multicenter cohort study provided
evidence of the potential prognostic and clinical utility of
baseline hematologic biomarkers in cutaneous melanoma
despite the lack of data for patients’ performance status and
comorbidities. We showed that low neutrophil–lymphocyte
and platelet–lymphocyte ratios, taken at the time of
definitive treatment for the primary tumor, were associated
with more than twice the risk of death from melanoma.
Moreover, the findings showed that SLNB-positive patients
can be stratified according to their NLR and PLR, which
could potentially help clinicians identify patients who may
benefit from adjuvant systemic therapy and enhanced
surveillance. Our findings concur with the evolving
hypothesis that host immunity is implicated in the survival
of patients with melanoma, whereby a pro-inflammatory
TABLE 2 Overall and melanoma-specific survival for patients stratified according to peripheral blood ratios
Baseline biomarker Crude risk Adjusted riska
HR (95% CI) p value HR (95% CI) p value Resampledb p value
Overall survival: individual biomarker
Continuous NLR 1.1 (1.0 to 1.2) 0.07 0.8 (0.6 to 1.0) 0.03 \ 0.001
PLR 1.0 (1.0 to 1.0) 0.9 1.0 (1.0 to 1.0) \ 0.001 \ 0.001
LMR 1.0 (0.9 to 1.1) 0.6 1.0 (0.9 to 1.1) 0.8 0.6
Dichotomized NLR \ 2.5 0.8 (0.6 to 1.1) 0.2 2.2 (2.0 to 2.3) \ 0.001 \ 0.001
C 2.5 1 (referent) 1 (referent)
PLR \ 100 1.2 (0.9 to 1.8) 0.2 1.8 (1.7 to 1.8) \ 0.001 \ 0.001
C 100 1 (referent) 1 (referent)
LMR \ 9 1 (referent) 0.3 1 (referent) 0.4 0.03
C 9 1.5 (0.6 to 3.8) 1.3 (0.6 to 2.6)
Overall survival: compound biomarker
NLR-low and PLR-low 1.1 (0.8 to 1.6) 0.02 3.0 (2.4 to 3.7) \ 0.001 \ 0.001
NLR-high or PLR-high 0.7 (0.5 to 0.9) 1.7 (1.1 to 2.7)
NLR-high and PLR-high 1 (referent) 1 (referent)
Melanoma-specific survival: individual biomarker
Continuous NLR 1.1 (0.9 to 1.2) 0.7 0.8 (0.6 to 1.0) 0.07 \ 0.001
PLR 1.0 (1.0 to 1.0) 0.6 1.0 (1.0 to 1.0) 0.05 \ 0.001
LMR 1.0 (0.9 to 1.1) 0.9 0.9 (0.9 to 1.0) 0.5 0.2
Dichotomized NLR \ 2.5 0.9 (0.7 to 1.3) 0.8 1.9 (1.6 to 2.2) \ 0.001 \ 0.001
C 2.5 1 (referent) 1 (referent)
PLR \ 100 1.4 (0.9 to 2.0) 0.1 1.9 (1.7 to 2.2) \ 0.001 \ 0.001
C 100 1 (referent) 1 (referent)
LMR \ 9 1 (referent) 0.8 1 (referent) 0.9 0.9
C 9 1.2 (0.4 to 3.8) 0.9 (0.2 to 4.8)
Melanoma-specific survival: compound biomarker
NLR-low and PLR-low 1.3 (0.9 to 2.0) 0.045 3.0 (2.0 to 4.2) \ 0.001 \ 0.001
NLR-high or PLR-high 0.8 (0.5 to 1.1) 1.4 (0.8 to 2.5)
NLR-high and PLR-high 1 (referent) 1 (referent)
HR hazard ratio; CI confidence interval; NLR neutrophil–lymphocyte ratio; PLR platelet–lymphocyte ratio; LMR lymphocyte-monocyte ratio
aEach biomarker was examined individually by Cox regression, with adjustment, for age, Breslow thickness (mm), and mitotic rate (per mm2) as
continuous variables; and for sex, ulceration, vascular invasion, tumor-infiltrating lymphocytes (TILs), regression, microsatellites, and sentinel
lymph node involvement as categorical variables. CIs are adjusted for clustering
bLossless non-parametric bootstrapping by resampling with replacement, with 1000 iterations. Low NLR was defined as\ 2.5, whereas high
NLR was defined as C 2.5. Low PLR was defined as\ 100, whereas high PLR was defined as C 100
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state may suppress or eradicate metastasis, explaining our
observed better survival of those with a high NLR (i.e., a
host inflammatory response).
Related research on melanoma survival and these
biomarkers has considered only advanced disease, whereas
we present data that applies to a greater proportion of
patients with early-stage melanoma. Davis et al.14 showed
that a baseline NLR higher than 3 was associated with a
25% increased risk of all-cause mortality. However, their
study considered patients with pT2b or worse tumors and
those presenting with nodal metastases. Accordingly, the
proportion of their cohort with Stage III disease was sub-
stantially greater than ours (49 vs 18%). Although Lino-
Silva et al.13 showed that an elevated baseline NLR (C 2)
was associated with 31% worse survival, lymph node
metastasis, and a higher risk of recurrence (although the
statistics for recurrence were not provided), 96% of their
cohort had acral lentiginous melanoma, and 41% had Stage
III disease.
Finally, several studies of immunotherapies for Stage IV
melanoma have shown an elevated baseline NLR to be
associated with adverse outcomes.10–12 Unlike Davis
et al.14 and Lino-Silva et al.,13 we found no univariable
association between NLR and survival. However, after
adjusting for confounding, we observed strong associations
between NLR/PLR and survival, but in the opposite
direction of the effect in the literature. This could mean that
elimination of confounding is important in early disease.
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FIG. 2 Kaplan-Meier plots of
a overall and b melanoma-
specific survival according to
the compound biomarker of the
neutrophil–lymphocyte ratio
(NLR) and the platelet–
lymphocyte ratio (PLR)
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Nonetheless, our data add to the evolving literature on
biomarkers in melanoma by providing important and new
data on patients with earlier-stage disease, which contra-
dicts the findings for Stage III13,14 and Stage IV
melanoma.10–12,14,18 We hypothesise that these biomarkers
may have a different prognostic role for patients with
localized disease, whereby a high NLR may be favorable
by indicating an inflammatory response to the melanoma.
Our estimates may be biased by selection because we do
not know why some patients had preoperative blood tests,
whereas others did not. Many individuals described in this
cohort study also were enrolled in an observational study of
the ‘‘normal’’ melanoma population23 that required FBC
monitoring. Therefore, uncertainty notwithstanding, we
believe this improves the external validity of our findings.
Equally, we did not measure factors associated with mel-
anoma outcome and biomarkers (e.g., obesity or ethnicity),
which may have confounded our estimates, explaining why
our findings contrast with the literature. Overall, the liter-
ature is deficient in peripheral blood biomarker research
concerning localized skin cancer, and we believe the
wealth of data on biomarkers in advanced cancers should
not be generalised to early melanoma without further
research.
The role of systemic inflammation in tumor progression
has been widely researched. Despite a wealth of literature
indicating a prognostic role of hematologic markers in
cancer, including two large systematic reviews of more
than 100 studies,7,21 few have sought to establish the
underlying inflammatory mechanism for these changes. In
healthy individuals, NLR but not PLR is associated with
systemic C-reactive protein (CRP) and interleukin 6 (IL-6)
levels,22 but the concordance between cytokines and
peripheral blood counts in outcome prediction remains to
be investigated. Furthermore, these processes may be
unique to tumor type, and currently, no published works
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FIG. 3 Kaplan-Meier plots of
a overall and b melanoma-
specific survival according to
sentinel lymph node status and
baseline compound biomarker
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exist that implicate specific cytokines in melanoma.
Widespread systemic inflammation in response to tumor
burden in metastatic disease could explain the associations
found between NLR and adverse outcomes for patients
with disseminated melanoma,10–12,18 but the reversed
association in our study suggests that inflammatory chan-
ges present in localized disease may be protective and,
more importantly, detectable in the peripheral blood.
Whether this subtle systemic inflammatory response (raised
NLR and PLR) protects against melanoma metastasis or
occurs in response to identified dissemination remains to be
determined.
We have shown that decreased peripheral lymphocyte
counts (as the NLR and LMR) are associated with
regression of the primary melanoma, which is difficult to
explain, particularly in the absence of any associations with
peripheral lymphocyte counts or the presence of TILs in
the primary tumor. This observation requires further
research.
CONCLUSION
The baseline NLR and PLR are significantly associated
with disease-specific and overall survival in cutaneous
melanoma. These biomarkers could potentially be useful in
routine clinical practice and future clinical trials to identify
patients who may benefit from adjuvant therapy and
enhanced surveillance.
ACKNOWLEDGMENT We thank Dr. Michele Cummings, B.Sc.,
Ph.D., Postdoctoral Research Fellow in Oncology and Scientific Lead
of the Women’s Health Research Group for her advice on the
investigation of biomarker thresholds using Cutoff Finder and sub-
sequent statistical modeling. We thank the University of Leeds for
funding this research. Ryckie G. Wade is an Academic Clinical
Fellow in Plastic Surgery, and this research was supported by the
National Institute for Health Research (NIHR) infrastructure at
Leeds although the views expressed in this article are those of the
authors and not necessarily those of the NIHR or the Department of
Health.
CONFLICT OF INTEREST There are no conflicts of interest.
OPEN ACCESS This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License (http://crea
tivecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a
link to the Creative Commons license, and indicate if changes were
made.
REFERENCES
1. Cancer Research UK. Skin Cancer Statistics (Internet), 2015.
Retrieved at http://www.cancerresearchuk.org/cancer-info/cance
rstats/types/skin/. Accessed October 2017.
2. Macbeth F, Newton-Bishop J, O’Connell S, et al. Melanoma:
summary of NICE guidance. BMJ 2015;351:h3708.
3. Coffelt SB, Wellenstein MD, de Visser KE. Neutrophils in can-
cer: neutral no more. Nat Rev Cancer. 2016;16:431–46.
4. Richards DM, Hettinger J, Feuerer M. Monocytes and macro-
phages in cancer: development and functions. Cancer
Microenviron. 2013;6:179–91.
5. Gay LJ, Felding-Habermann B. Contribution of platelets to
tumour metastasis. Nat Rev Cancer. 2011;11:123–34.
6. Ray-Coquard I, Cropet C, Van Glabbeke M, et al. Lymphopenia
as a prognostic factor for overall survival in advanced carcino-
mas, sarcomas, and lymphomas. Cancer Res. 2009;69:5383–91.
7. Templeton AJ, McNamara MG, Sˇeruga B, et al. Prognostic role
of neutrophil-to-lymphocyte ratio in solid tumors: a systematic
review and meta-analysis. JNCI J Natl Cancer Inst.
2014;106:124.
8. Templeton AJ, Ace O, McNamara MG, et al. Prognostic role of
platelet-to-lymphocyte ratio in solid tumors: a systematic review
and meta-analysis. Cancer Epidemiol Prev Biomarkers.
2014;23:1204–12.
9. Nishijima TF, Muss HB, Shachar SS, Tamura K, Takamatsu Y.
Prognostic value of lymphocyte-to-monocyte ratio in patients
with solid tumors: a systematic review and meta-analysis. Cancer
Treat Rev. 2015;41:971–8.
10. Ferrucci PF, Gandini S, Battaglia A, et al. Baseline neutrophil-to-
lymphocyte ratio is associated with outcome of ipilimumab-
treated metastatic melanoma patients. Br J Cancer.
2015;112:1904–10.
11. Zaragoza J, Caille A, Beneton N, et al. High neutrophil-to-lym-
phocyte ratio measured before starting ipilimumab treatment is
associated with reduced overall survival in patients with mela-
noma. Br J Dermatol. 2016;174:146–51.
12. Khoja L, Atenafu EG, Templeton A, et al. The full blood count as
a biomarker of outcome and toxicity in ipilimumab-treated
cutaneous metastatic melanoma. Cancer Med. 2016;5:2792–9.
13. Lino-Silva LS, Salcedo-Herna´ndez RA, Garcı´a-Pe´rez L, Mene-
ses-Garcı´a A, Zepeda-Najar C. Basal neutrophil-to-lymphocyte
ratio is associated with overall survival in melanoma. Melanoma
Res. 2017;27:140–4.
14. Davis JL, Langan RC, Panageas KS, et al. Elevated blood neu-
trophil-to-lymphocyte ratio: a readily available biomarker
associated with death due to disease in high-risk nonmetastatic
melanoma. Ann Surg Oncol. 2017;24:1989–96.
15. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL TA.
AJCC Cancer Staging Manual. 7th ed. Springer New York, LLC,
New York, NY, 2010.
16. Sladden M, Zagarella S, Popescu C, Bigby M. No survival benefit
for patients with melanoma undergoing sentinel lymph node
biopsy: critical appraisal of the Multicenter Selective Lym-
phadenectomy Trial I–final report. Br J Dermatol.
2015;172:566–71.
17. Cananzi FCM, Dalgleish A, Mudan S. Surgical management of
intraabdominal metastases from melanoma: role of the neu-
trophil-to-lymphocyte ratio as a potential prognostic factor.
World J Surg. 2014;38:1542–50.
18. Gandini S, Ferrucci PF, Botteri E, et al. Prognostic significance of
hematological profiles in melanoma patients. Int J Cancer.
2016;139:1618–25.
19. Budczies J, Klauschen F, Sinn B V, et al. Cutoff Finder: a
comprehensive and straightforward Web application enabling
rapid biomarker cutoff optimization. PLoS One. 2012;7:e51862.
20. Moons KG, Altman DG, Reitsma JB, et al. Transparent reporting
of a multivariable prediction model for individual prognosis or
diagnosis (TRIPOD): explanation and elaboration. Ann Intern
Med. 2015;162:W1–73.
3348 R. G. Wade et al.
21. Guthrie GJK, Charles KA, Roxburgh CSD, et al. The systemic
inflammation-based neutrophil–lymphocyte ratio: experience in
patients with cancer. Crit Rev Oncol Hematol. 2013;88:218–30.
22. Lin BD, Hottenga J-J, Abdellaoui A, et al. Causes of variation in
the neutrophil–lymphocyte and platelet–lymphocyte ratios: a
twin-family study. Biomark Med. 2016;10:1061–72.
23. Newton Bishop JA. Answering Questions About Vitamin D
Supplementation and Sun Exposure in Patients Who Have
Undergone Surgery for Stage IB, Stage II, or Stage IIIA Mela-
noma. Retrieved at https://clinicaltrials.gov/ct2/show/N.
Accessed October 2017.
Baseline NLR and PLR and Survival in Melanoma 3349
